Currently Enrolling Research Trials

Current Research Projects


Immune checkpoint inhibitor myocarditis is an uncommon toxicity associated with the use of immune checkpoint inhibitors in cancer but is associated with a rate of major adverse cardiac events that is greater than 50%. There are case reports and robust basic data to support the hypothesis that abatacept may be beneficial among patients with immune checkpoint inhibitor myocarditis. However, there are no rigorous data. In the ATRIUM trial (ATRIUM Brief Overview Image), 390 patients with immune checkpoint myocarditis will be randomized to usual care or usual care plus abatacept. The study design is a double blind placebo controlled trial ( The ATRIUM study is an investigator-initiated study and is actively recruiting. The sponsor is Massachusetts General Hospital. In the ATRIUM trial, patients hospitalized with immune checkpoint associated myocarditis will be randomized to abatacept (10 mg/kg) or placebo administered after randomization, again at not greater than 24 hours, at 14 days and there is an optional 4th dose at 28 days (ATRIUM Image 2). Study participants are followed for 6 months for the development of major adverse cardiac events. The investigators plan to have the ATRIUM trial open at 50 sites in the United States and Canada (ATRIUM Image 3).

If your center is interested in hearing more about the ATRIUM study, please contact the ATRIUM study team at or one of the co-principal investigators: Tom Neilan - or Paul Ridker

Notice of Special Interest (NOSI): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity

Read More


PROactive evaluation of function to Avoid CardioToxicity


Understanding and Predicting Breast Cancer Events After Treatment


CardiovaScUlar toxicity in cancer and improvement In recovery